{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005618","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.471208+00:00","generated_at":"2026-05-30T14:31:00.183921+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers","bullets":["Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.","Late-breaking posters will show IM-PROVE I and IM-PROVE II Phase 2a trial data.","Immune biomarker profiling in subjects treated with imdusiran + pegylated interferon reveals phases of immune activation linked to HBsAg seroconversion.","Imdusiran target site is highly conserved across HBV genotypes A-E; SNPs do not affect HBsAg decline.","Posters will be available on Arbutus website from November 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005618","json":"https://secwatch.observer/filing/0001171843-24-005618.json","markdown":"https://secwatch.observer/filing/0001171843-24-005618.md","text":"https://secwatch.observer/filing/0001171843-24-005618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/0001171843-24-005618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/f8k_101524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:31:00.183921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}